ALT down big again. I bought a little I agree there may be room to mitigate some AEs w titration as you say but also dose reduction (it wasn’t allowed in the phase 2). They could carve out a niche here w any small differences in the profile and given the size of the overall market that could be valuable.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.